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Abstract: In hypertensive subjects, cardiovascular risk reduction is critically related to the 
decrease of systolic blood pressure (SBP). De-stiffening therapy means that, in a controlled 
therapeutic trial of long duration, a selective reduction of SBP has been obtained in the 
studied group by comparison with the control group, and that this SBP reduction is due to 
a decrease of either arterial stiffness, or wave reflections, or both. Central SBP reduction 
and cardiovascular remodeling are specifically involved. Most protocols require the pres-
ence of an angiotensin II blocker, potentially associated with a diuretic compound and/or a 
calcium-channel blocker. Cardiovascular outcomes are significantly reduced by comparison 
with the control group, particularly when this latter group involves administration of a beta-
blocking agent.
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Introduction
A reduction in SBP has explained most of the treatment benefit in outcome trials in 
patients with hypertension.1–6 This benefit has been obtained mostly using ANG-II 
inhibition. Such findings focused attention on the factors that modulate SBP and PP 
levels in hypertensive individuals, and therefore on the role of increased arterial stiff-
ness and/or wave reflections in the mechanism of hypertension.
This review has four parts: 1) Mechanisms of propagation of the pressure wave 
along the vascular circuit; 2) Pulsatile arterial hemodynamics as independent predic-
tors of CV risk; 3) Relationship between pulsatile arterial hemodynamics and renin-
angiotensin system; and 4) Principal strategies for lowering large artery stiffness in 
the treatment of hypertension and CV prevention.
Mechanisms of pressure wave propagation 
along the vascular tree
There are two components of pressure and flow: a steady component and a pulsatile 
component. The former is represented by MAP, the product of blood flow by vascular 
resistance, an index of the “caliber” of small arteries. The latter is represented by PP, 
which is determined by stroke volume, arterial stiffness and wave reflections. The 
second two factors, but not stroke volume, are influenced by the ability to change the 
cyclic flow coming from the heart into a continuous flow at the peripheral level in 
order to obtain an adequate oxygenation of tissue.Integrated Blood Pressure Control 2010:3 
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Blood pressure propagation, arterial 
stiffness and wave reflections
Following ventricular contraction, the pressure pulse generated 
by the heart travels along the aorta as a wave (Figure 1). It is 
possible to calculate the velocity of propagation of this wave 
(ie, PWV) along the aorta from the interval between two BP 
curves located at two different sites in the arterial tree (Figure 1). 
Because of the fundamental principle is that pulse waves travel 
faster in stiffer arteries, PWV measurement is considered the 
best surrogate to evaluate arterial stiffness. Its value is 3 to 5 m/s 
in young persons at rest, but increases considerably with age 
(Figure 1). Given that peripheral arteries are markedly stiffer 
than central arteries, an important feature of PWV determina-
tions is the large heterogeneity of the arterial tree.
When BP measurements are made simultaneously at 
different points along the aorta, the pressure wave changes 
shape as it travels down the aorta (Figure 2). Whereas SBP 
actually rises with distance from the heart, the DBP and 
MAP fall slightly (about 4 mm Hg) during the same course 
along the aortic trajectory. Thus, pressure-oscillation ampli-
tude between systole and diastole, which is represented by 
PP (Figure 3) nearly doubles. This SBP and PP amplifica-
tion (Figure 2) is a physiological finding, approximately 
14 mm Hg between the thoracic aorta root and the brachial 
artery, and continuing in aortic ramifications out to about the 
third-generation level of branches. Thereafter, both PP and 
MAP drop sharply to the levels found in the microcirculation, 
a vascular area in which steady flow is nearly achieved.
If an individual’s body length is about 2 m at most, and 
aortic PWV is approximately 5 m/s, something must happen 
to the shape of the BP curve within each beat if heart rate 
is 60/min, which is the generation of wave reflections and 
their summation with the incident wave, as summarized in 
Figure 2. The incident wave is driven away from the heart 
through the highly conductive arteries. However, it encoun-
ters an impedance mismatch at the junction of the highly 
conductive artery and highly resistant arterioles, blocking 
its entry into the arterioles, and it is reflected, traveling 
backwards towards the heart (Figure 2). Thus, the shape of 
every pulse wave results from the summation of the incident 
(forward-traveling) and reflected (backward-traveling) pres-
sure waves (Figure 3).
role of age on BP curve and wave 
reflections
Reflected waves may be initiated from any discontinuity of 
the arterial or arteriolar wall, but are mainly issued from high 
resistance vessels.1,2 Pulse-wave propagation and reflection 
vary considerably according to age. In young adults at their 
maximum height and maximum elasticity of their central 
arteries (low PWV), the summation of the incident arterial 
pressure wave and the reflected wave results in progressive 
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Figure  Clinical determination of Pwv. Pwv is the ratio between: 1) the distance between the carotid and femoral transducers (L), and 2) the time delay (∆T) between the 
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PP amplification, so that SBP is higher in the brachial artery 
than the ascending aorta (Figure 3). This hemodynamic pro-
file contrasts with MAP and DBP, which decline minimally 
in vessels at increasing distance from the heart at all ages 
(Figure 2). Note that, in the thoracic aorta, because PWV is 
relatively low, the reflected wave comes back during diastole, 
thereby maintaining DBP and boosting coronary perfusion 
(Figure 3, lower part). Hence, an optimal arterial function is 
maintained, along with adequate coronary perfusion.
The pattern of wave reflections and the pulse wave shape 
are directly dependent on aging and arterial stiffness. The 
development of increasing arterial stiffness (high PWV) 
and altered wave reflections with aging and hypertension 
completely abolishes the differences between central and 
peripheral PP by age 50 to 60 years, with major consequences 
for ventricular load and coronary perfusion. The increased 
PWV means that the reflected waves return to the aortic root 
earlier, during late systole. In this situation, the reflected 
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Figure  Progression of the pressure wave along the aortic tree.   Three steps are involved: propagation, reflection, and summation of the incident and the reflected waves.
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Figure  The upper part gives a schematic representation of the BP curve on the right, and the forward and reflected wave on the left. In the lower part, the BP curve is 
represented in younger (on the left) and in older (on the right) subjects.   Augmentation index (AIx) is the ratio between: 1) the difference between peak SBP and the shoulder 
of the ascending part of the BP curve, and 2) pulse pressure.   AIx, measured in %, represents the supplementary increase in SBP due to wave reflections. This hemodynamic 
profile is observed in the elderly, not in young people. MAP is mean arterial pressure, corresponding to the steady pressure necessary to a continuous cardiac pump.Integrated Blood Pressure Control 2010:3 
Safar Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
waves combine with the forward-traveling wave to create an 
increased “augmentation” of the central SBP and ventricular 
load (Figure 3, lower part). In elderly persons with isolated 
systolic hypertension, aortic SBP can be elevated by a much 
as 30 to 40 mm Hg as a result of the early return of the wave 
reflection.1,2 Furthermore, because the backward pressure 
returns in systole, and not in diastole, as a consequence of 
enhanced PWV , DBP and coronary blood flow tend to be 
reduced, a situation favoring coronary ischemia. Finally, the 
classical phenotype of systolic hypertension in the elderly is 
observed (Figure 3). It is worth noting that reduced heart rate 
shifts wave reflection from diastole in systole, thus increasing 
central SBP. Inversely, angiotensin and calcium blockade 
as well as insulin reduce wave reflection and central SBP. 
Insulin resistance has an opposite effect.
Mechanical forces and vascular 
remodeling
It is important to note that an arterial wall is a complex tissue 
composed of different cell populations capable of structural 
and functional changes, in response to direct injury and athero-
genic factors, or to modifications of long-term hemodynamic 
conditions. The principal geometric modifications induced by 
hemodynamic alterations are changes of the arterial lumen 
and/or arterial wall thickness due to activation, proliferation 
and migration of VSM cells, and rearrangements of cellular 
elements and ECM.1,3–8 Chronic alterations of mechanical 
forces lead to modifications of the geometry and composi-
tion of the vessel walls, as observed in hypertension, par-
ticularly in the elderly.1,2,7 To maintain tensile stress within 
physiological limits, arteries respond by thickening their walls 
(Laplace’s law). On the other hand experimental and clinical 
data indicate that acute and chronic augmentations of arterial 
blood flow induce proportional increases of the vessel lumen, 
whereas diminished flow leads to reduction of the inner arte-
rial diameter.1,2,9 The presence of the endothelium is a major 
prerequisite for normal vascular adaptation to chronic changes 
of blood flow and pressure.
Hypertensive remodeling is characterized by the increased 
wall/lumen ratio of arterioles, which represent the site of 
vascular resistance and also the origin of wave reflections 
(Figure 1).9–12 Regression of arteriolar hypertrophy is associated 
with diminution of vascular resistance and of reflection coef-
ficients, thereby causing a lower SBP, PP and AIx, a classical 
marker of wave reflections (Figure 3, lower side).10–12 This 
process occurs approximately after 1-year of treatment in 
hypertensive subjects under angiotensin or calcium blockade, 
but not under thiazide diuretics and/or beta-blocking agents.11 
Endothelial dysfunction may sometimes participate to this 
process, mainly through NO deficiency and development of 
oxidative stress.1,2,9–13
Pulsatile arterial hemodynamics 
as independent predictors of CV risk
This section will show how brachial PP, aortic PWV , and 
to a greater extent central PP and wave reflections, are inde-
pendent predictors of CV risk, implicating the possibility 
of specific drug treatments, called de-stiffening therapy, in 
relation with pulsatile arterial hemodynamics.
Brachial PP
Following the seminal works by Darné et al and Madhavan 
et al,14,15 several authors showed almost simultaneously16–18 that, 
after 50 to 60 years of age, brachial PP was a strong CV risk 
factor for myocardial infarction in populations of hypertensive 
individuals. The best predictor function of all possible linear 
combinations of SBP and DBP was shown to be similar to 
that of PP, indicating that their association was not a statistical 
artefact caused by the correlation between SBP and PP.18 The 
result was independent of MAP and stronger than for SBP. As 
shown in Figure 4, CV risk rises sharply with SBP. However, 
at any given SBP value, CV risk is higher when DBP is lower, 
ie, when PP is increased.17 This important finding was con-
firmed by the result of a longitudinal study,19 which indicated 
that, during a 20 years follow-up, subjects with higher CV 
mortality were those whose SBP rose and DBP declined, and 
their CV mortality rate was significantly higher than that for 
those individuals whose SBP and DBP increased.19 Finally, it 
was demonstrated that, in the elderly, neither SBP nor DBP was 
superior to PP for predicting coronary risk and PP was found to 
be an independent predictor of CV mortality, even under drug 
treatment of hypertension.20,21 Similar results were obtained for 
individuals with recurrent myocardial infarction, congestive 
heart failure or myocardial dysfunction. Finally, brachial PP 
was shown to be predictor of CV risk in subjects with ESRD, 
diabetes mellitus or even systemic vasculitis.22–25
Aortic Pwv
More recently, aortic PWV , a classic index of arterial stiff-
ness, was shown to be an independent predictor of CV 
mortality in hypertensive individuals.
Based on the characteristics of patients26 with ESRD, 
logistic-regression and Cox analyses identified for the first 
time that the odds ratios for PWV (12 m/s) were 5.6 (95% 
CI 2.4 to 11.9 for all-cause mortality, and 5.9 (95% CI 2.3 
to 15.5) for CV mortality. Furthermore, while the carotid Integrated Blood Pressure Control 2010:3 
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wall/lumen ratio did not predict CV risk, carotid stiffness 
itself and carotid wave reflections (and not wall thickness) 
were a significant predictor of CV mortality.27,28 Similar 
observations were obtained for ESRD patients with diabetes 
mellitus29 and for kidney-transplant recipients.30
In subjects with essential hypertension, Blacher et al31 
showed that CV risk assessed using Framingham equations 
was linearly associated with the PWV increase. Furthermore, 
the odds ratio of being at high risk of CV mortality (5% for 
10 years) for patients with PWV  13.5 m/s was 7.1 (95% 
CI 4.5 to 11.3). That study32 provided the first evidence that 
a single aortic PWV measurement could be a strong inde-
pendent predictor of CV risk for hypertensive patients. The 
results of longitudinal studies32–36 confirmed that aortic PWV 
is a significant and independent predictor of CV risk, more 
potent than PP itself.
Central PP
Studies of pulsatile arterial hemodynamics showed that, 
while MAP remains nearly constant along the arterial tree, 
PP rises markedly from central (thoracic aorta and carotid 
artery) to peripheral (brachial) arteries. This physiological 
amplification can be explained because the pressure-wave 
propagation along arterial vessels is associated with a 
progressive artery-diameter decline and arterial stiffness 
increase, resulting in modifications of wave-reflections 
(timing and/or amplitude). Therefore, aortic PP is expected 
to be more relevant to the investigation of CV risk than 
brachial PP, because it is closer to the heart, coronary arter-
ies and carotid arteries, which are the most important sites 
of CV events.1,2 Aortic, but not brachial, pulsatility has 
been shown to be independently associated with CAD in 
patients undergoing coronary angiography before or after 
angioplasty.32,37,38 Furthermore, in 409 subjects followed 
for 4 to 5 years by Jankowski et al,39 a 10-mm Hg aortic PP 
increase was associated with a corresponding 13% increase 
of CV events. In atherosclerotic subjects, central wave reflec-
tions were shown to be independent predictors of CAD.39 
In ESRD patients, aortic PWV and carotid wave reflections 
(and/or central PP) were shown to predict independently 
CV mortality.1,2,40 Finally, in the same ESRD patients and in 
elderly subjects with essential hypertension, central PP was 
demonstrated to be an independent predictor of mortality.41 
Taken together, all these findings suggest that central PP 
was superior to brachial PP for prediction of coronary risk 
and indicate that, during long-term antihypertensive drug 
therapy, serial central BP determinations are required to 
predict CV complications and justify the development of 
new de-stiffening strategies enabling to prevent CV risk.2
Pulsatile arterial hemodynamics 
and renin-angiotensin system
ANG-II blockade is classically associated with reduction of 
vascular resistance and MAP. In contrast, the effects on PWV 
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Figure  Curves plotting the 2-year risk of Cv events in the elderly as a function of increasing SBP.  Note that, at each given SBP value, the Cv risk was higher when baseline 
DBP was lower. reproduced with permission from Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive 
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and central and peripheral PP have been poorly investigated 
until recently. Studies on animal models and in humans 
suggest that ANG-II blockade is associated with reverse 
remodeling of both small and large arteries via specific mecha-
nisms including anti-inflammatory and antifibrotic effects as 
well as changes of arterial attachments linking α5β1-integrin 
to its specific ligand fibronectin.42–44 Such effects are very 
important to consider in order tp obtain a significant and 
selective reduction of central PP and arterial stiffness under 
ANG-II blockade. They affect both small and large arteries 
and are acting through the MAP-kinase system.10,44
In hypertensive rats under low-salt diet (but not under 
high-salt diet), ANG-II blockade by the ARB valsartan 
normalizes central PP (50 mm Hg) but not MAP for the 
same drug dosage.42,43 In hypertensive subjects under ANG-
II blockade, not only PWV is decreased independently of 
MAP but also central wave reflections are attenuated and 
carotid-brachial SBP and PP amplification are increased. 
ANG-II blockade improves, or even normalizes, the wall 
thickness of small resistance arteries, and at the same time, 
reduces pressure wave reflections, suggesting a cause/effect 
relationship between the two factors.1,5 The arterial proper-
ties do not differ consistently whether ACEI or ARB are 
used and are the basis of all new strategies using de-stiffen-
ing therapy.
The Reason study10,45 was the first to investigate the 
long-term interactions among PP, arterial stiffness and wave 
reflections in relationship to drug treatment and end-organ 
damage (cardiac mass) in hypertensive subjects of the middle 
age. The ACEI Per, associated with low-dose Ind, was com-
pared for 1 year of treatment with the beta-blocking agent 
atenolol. For the same DBP and MAP decreases, Per/Ind 
lowered SBP and PP more than atenolol (Figure 5). The 
reduction was more pronounced centrally (carotid artery) than 
peripherally (brachial artery). While the two drug regimens 
lowered PWV equally, only Per/Ind reduced central PP and 
AIx.10,45 In addition, Per/Ind decreased cardiac hypertrophy 
more than atenolol, and this diminution was attributed to the 
AIx decrease, indicating that the reduction of cardiac end-
organ damage reflected mainly an effect on central wave 
reflections.10,45 Under drug treatment, the lowering of SBP 
was significantly predicted by baseline PWV .
De-stiffening strategy and BP control
ANG-II blockade and diuretics
The main therapeutic trial demonstrating the predictive role 
of aortic stiffness in hypertensive subjects was conducted in 
ESRD patients on hemodialysis.46 The objective of that trial 
was to lower CV morbidity and mortality through a therapeutic 
regimen involving successively: salt and water depletion by 
Blood pressure changes
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Figure  Central (C) and brachial (B) BP of the reASON study before and after one year treatment 10.   whereas the DBP reduction was similar for the 2 groups of subjects, 
the reduction of SBP and mostly of PP was more pronounced on central than brachial arteries, in favour of Per/Ind when compared to atenolol. reproduced with permission 
from Asmar et al 2001. Hypertension. 2001;38:922–926.52 Copyright © 2001 American Heart Association.Integrated Blood Pressure Control 2010:3 
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dialysis; then, after randomization, ACEI or CCB; and, finally, 
the combination of the two agents and/or their association 
with a beta-blocker. Using that protocol, it was possible to 
evaluate, over long-term follow-up (51 months), whether or 
not the drug-induced MAP reduction was associated with a 
parallel diminution of PWV impacting on CV risk. During 
follow-up, it was evident that survivors’ MAP, brachial PP and 
aortic PWV were lowered in parallel. In contrast, for patients 
who died from CV events, MAP had been reduced to the same 
extent as in survivors, but drug treatment had not significantly 
modified PWV or brachial PP. Thus, survival of ESRD patients 
was significantly better when aortic PWV declined in response 
to BP lowering. The adjusted relative risks for all-cause and 
CV mortality rates in those with unchanged PWV in response 
to BP changes were respectively: 2.59 (95% CI, 1.51 to 4.43) 
and 2.35 (95% CI, 1.23 to 4.51) (P  0.01). The prognosis 
value of PWV sensitivity to BP reduction on survival was 
independent of age, BP changes and blood-chemistry abnor-
malities (Figure 5).The results indicated that arterial stiffness 
was not only a risk factor contributing to the development of 
CV disease but also that it was a marker of established, more 
advanced and less reversible arterial lesions. This interpreta-
tion was supported by the loss of aortic PWV sensitivity to 
BP lowering for nonsurvivors, compared to survivors whose 
arterial stiffness remained responsive to BP reduction. Finally, 
in that trial, prolonged survival seemed to be more closely 
associated with the use of an ACEI than other drugs or the 
number of drugs per se. The use of beta-blockers and/or CCB 
had no direct impact on the outcomes.46
In diabetes subjects, the Per/Ind combination was stud-
ied in double-blind vs placebo with or without intensive 
glucose therapy. The BP control was followed for 4.3 years 
in 11,340 subjects. Reduction of BP was associated with 
a reduction of overall and CV mortality. The prediction of 
CV mortality was significant for brachial artery SBP and 
PP but not for MAP and DBP. It is worth noting that only 
diabetes mellitus, and not BP, was the criterion of selection 
of ADVANCE.47 However, the predictive values were in 
agreement with those of REASON.53
ANG-II blockade and CCB blockade
The CAFE study, a subanalysis of the ASCOT trial 48, 
conducted on 2073 subjects, showed that aortic PP, recorded 
noninvasively by radial tonometry and the application of 
generalized transfer functions, was a determinant of clinical 
outcomes, independently of age, other traditional CV risk fac-
tors and even peripheral PP. In agreement with the REASON 
study,10,45 the results of the CAFE study showed that treating 
subjects with a regimen based on the beta-blocker atenolol 
and a diuretic versus one based on the CCB amlodipine and 
an ACEI had similar effects on brachial SBP and PP but 
different effects on central aortic pressures.48 Even though 
brachial pressure reductions were similar for the two arms of 
the study, central SBP and PP decreases were greater for the 
CCB amlodipine and the ACEI Per arm. That study’s results 
not only demonstrated that brachial PP does not always reflect 
the effect of different pressure-lowering treatments on cen-
tral aortic pressures, but also suggested that central pressure 
changes might better predict clinical outcomes other than 
brachial pressures.48 Therefore, antihypertensive drug therapy 
should selectively lower SBP and PP through complex interac-
tions between small and large artery effects, thereby opening 
the way for the development of new long-term CV-treatment 
strategies involving both small and large arteries.
The comparison effects between a CCB and a diuretic in 
combination with the same ARB OLM were studied using aor-
tic SBP and brachial ambulatory SBP.49 This was a prospective, 
randomized, open-label, blinded end-point study in 207 hyper-
tensive patients (mean age: 68.4 years). Patients received OLM 
monotherapy for 12 weeks, followed by additional use of AZE 
(n = 103) or hydrochlorothiazide (n = 104) for 24 weeks after 
randomization. After adjustment for baseline covariates, the 
extent of reduction in central SBP of the OLM/AZE group was 
significantly greater than that in the OLM/DIURETIC group 
(between-group difference 95% CI 5.2 0.3 to 10.2 mm Hg, 
P = 0.039), while the difference in the reduction in brachial 
SBP between the groups was not significant (2.6 to 2.2 to 
7.5 mm Hg, P = 0.29. The aortic PWV showed a significantly 
greater reduction for the OLM/AZE combination than for the 
OLM/DIURETIC combination (08 0.5 to 1.1 m/s, P  0.001) 
after adjustment for covariates. The extent of reduction in bra-
chial ambulatory SBP was similar between the groups. These 
data showed that the combination of OLM 20 mg/AZE 16 mg 
had a more beneficial effect on central SBP and arterial stiff-
ness than the combination of OLM 20 mg/hydrochlorothiazide 
12.5 mg, despite the lack of a significant difference in brachial 
SBP reduction between the two treatments.
In the present study, Matsui et al49 have provided evidence 
on the mechanism of reduction of SBP and PP amplification by 
CCB, namely by reducing PWV and AIx. CCB is a powerful 
vasodilating agent, increasing the large artery diameter indepen-
dently of BP reduction and of any endothelium-dependent effect. 
Reduction of pressure wave reflections is the second important 
mechanism of central SBP reduction by CCB. Although heart 
rate was decreased in the OLM/AZE arm, thus favoring an 
earlier timing of wave reflections in systole, AI was reduced. Integrated Blood Pressure Control 2010:3 
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This may be explained partly by the prolonged time of return 
of the reflected wave, due to lower PWV . Another possibility is 
that the long-term drug treatment causes regression of arteriolar 
hypertrophy as usually observed under CCB treatment. This 
might cause distal shift of reflections sites or decrease of reflec-
tion coefficients, thus lowering amplitude of wave reflections.5 
The same possibility may be observed with ANG-II blockade, 
but not with diuretic or traditional beta-blocking agents given 
alone.50 Whether AZE has such effects, most likely via arterio-
lar vasodilatation and structural changes, or by altering baro-
reflex sensitivity, or even acting synergistically with ANG-II 
blockade,51 are possibilities that merit further exploration.
In conclusion, this report has shown that it is possible to 
obtain in the long term a selective reduction of brachial and 
mostly central PP through a decrease of arterial stiffness and 
wave reflections. Most of the therapeutic protocols involve 
angiotensin blockade. Because CV reduction is dominantly 
related to the control of SBP, the de-stiffening strategy should 
be now extensively developed.
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